Showing results (131-140 of 140) with videos related to
Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
The Lancet. Oncology|May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Seock-Ah Im, Marco Colleoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.Lancet (London, England)|December 10, 2022
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialSara A Hurvitz, Roberto Hegg, Wei-Pang Chung, et al.The New England Journal of Medicine|April 21, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerAditya Bardia, Sara A Hurvitz, Sara M Tolaney, et al.The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2021
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast CancerCarmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 18, 2021
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021William J Gradishar, Meena S Moran, Jame Abraham, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 12, 2023
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023William J Gradishar, Meena S Moran, Jame Abraham, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Meena S Moran, Jame Abraham, et al.Pageof 14